Associated Papers
Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery.
Liu Y et al.
Journal of Cardiovascular Development and Disease, 2025
Integrative structural profiling and ligand optimisation across the transthyretin mutational landscape.
Lomoio U et al.
Npj Systems Biology and Applications, 2025
40998828 (PubMed )
Supplement: 41540_2025_582_MOESM1_ESM.pdf
A Multicenter Study of Hereditary Transthyretin Amyloidosis in China.
Chu X et al.
Annals of Neurology, 2025
Cognitive manifestations and brain integrity in hereditary transthyretin amyloidosis: a systematic review.
Senem I et al.
Journal of Neurology, 2025
Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
Nagano N et al.
International Heart Journal, 2022
Application of optical coherence tomography angiography to assess systemic severity in patients with hereditary transthyretin amyloidosis.
Kakihara S et al.
Plos One, 2022
Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by E61K mutation.
Chu X et al.
Frontiers in Molecular Neuroscience, 2022
Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.
Patel RK et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis, 2021
Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val.
Shan H et al.
Stem Cell Research, 2020
Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.
Rowczenio D et al.
Human Mutation, 2019
Ophthalmological manifestations of hereditary transthyretin amyloidosis.
Gondim FAA et al.
Arquivos Brasileiros De Oftalmologia, 0
Select a paper to view details